Ocumension Therapeutics (HKG:1477) reported 132.3 million yuan in loss for the first half of 2025, narrowing from a loss of 151.3 million yuan a year earlier, according to a Thursday filing with the Hong Kong bourse.
Loss per share was 0.17 yuan, compared with 0.23 yuan in the prior year.
Revenue at the drug company increased 75% year-on-year to 294 million yuan, figures showed.
Meanwhile, in a separate announcement, the company said its OT-301 drug candidate met the main goal of a second late-stage study.
The drug was found to be non-inferior to the current standard of care latanoprost in the phase 3 Denali trial of subjects with an eye condition called pen-angle glaucoma or ocular hypertension.
As a result, the medicine now meets the requirements for new drug approval in China, the firm said.
Ocumension Therapeutics is developing OT-301, also known as NCX 470, with Nicox.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。